Ceramides and Phosphatidylcholines Associate with Cardiovascular Diseases in the Elderly.


Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
06 12 2022
Historique:
received: 23 12 2021
accepted: 09 08 2022
pubmed: 30 10 2022
medline: 21 12 2022
entrez: 29 10 2022
Statut: ppublish

Résumé

The ceramide- and phospholipid-based cardiovascular risk score (CERT2) has been found to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular mortality. In the present study, our aim was to estimate the predictive ability of CERT2 for mortality of CVD, coronary artery disease (CAD), and stroke in the elderly and to compare these results with those of conventional lipids. We conducted a prospective study with an 18-year follow-up period that included a total of 1260 participants ages ≥64 years. Ceramides and phosphatidylcholines were analyzed using a LC-MS. Total cholesterol and triglycerides were performed by enzymatic methods and HDL cholesterol was determined by a direct enzymatic method. Concentrations of LDL-cholesterol were calculated according to the Friedewald formula. A higher score of CERT2 was significantly associated with higher CVD, CAD, and stroke mortality during the 18-year follow-up both in unadjusted and adjusted Cox regression models. The unadjusted hazard ratios (HRs) of CERT2 (95% CI) per SD for CVD, CAD, and stroke were 1.72 (1.52-1.96), 1.76 (1.52-2.04), and 1.63 (1.27-2.10), respectively, and the corresponding adjusted HRs (95% CI) per SD for CERT2 were 1.48 (1.29-1.69), 1.50 (1.28-1.75), and 1.41 (1.09-1.83). For conventional lipids, HRs per SD were lower than for CERT2. The risk score CERT2 associated strongly with CVD, CAD, and stroke mortality in the elderly, while the association between these events and conventional lipids was weak.

Sections du résumé

BACKGROUND
The ceramide- and phospholipid-based cardiovascular risk score (CERT2) has been found to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular mortality. In the present study, our aim was to estimate the predictive ability of CERT2 for mortality of CVD, coronary artery disease (CAD), and stroke in the elderly and to compare these results with those of conventional lipids.
METHODS
We conducted a prospective study with an 18-year follow-up period that included a total of 1260 participants ages ≥64 years. Ceramides and phosphatidylcholines were analyzed using a LC-MS. Total cholesterol and triglycerides were performed by enzymatic methods and HDL cholesterol was determined by a direct enzymatic method. Concentrations of LDL-cholesterol were calculated according to the Friedewald formula.
RESULTS
A higher score of CERT2 was significantly associated with higher CVD, CAD, and stroke mortality during the 18-year follow-up both in unadjusted and adjusted Cox regression models. The unadjusted hazard ratios (HRs) of CERT2 (95% CI) per SD for CVD, CAD, and stroke were 1.72 (1.52-1.96), 1.76 (1.52-2.04), and 1.63 (1.27-2.10), respectively, and the corresponding adjusted HRs (95% CI) per SD for CERT2 were 1.48 (1.29-1.69), 1.50 (1.28-1.75), and 1.41 (1.09-1.83). For conventional lipids, HRs per SD were lower than for CERT2.
CONCLUSIONS
The risk score CERT2 associated strongly with CVD, CAD, and stroke mortality in the elderly, while the association between these events and conventional lipids was weak.

Identifiants

pubmed: 36308332
pii: 6779897
doi: 10.1093/clinchem/hvac158
doi:

Substances chimiques

Ceramides 0
Phosphatidylcholines 0
Cholesterol, LDL 0
Cholesterol, HDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1502-1508

Commentaires et corrections

Type : CommentIn

Informations de copyright

© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Taina T Katajamäki (TT)

Faculty of Medicine, Department of Clinical Medicine, Unit of Clinical Chemistry, Turku University, Turku, Finland.
Department of Clinical Chemistry, Laboratory Division, Turku University Hospital, Hospital District of Southwest Finland, Turku, Finland.

Marja-Kaisa Koivula (MK)

HUS Diagnostic Center, Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.
Clinical Chemistry and Hematology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Mika Hilvo (M)

Zora Biosciences Oy, Espoo, Finland.

Mitja T A Lääperi (MTA)

Zora Biosciences Oy, Espoo, Finland.

Marika J Salminen (MJ)

Faculty of Medicine, Department of Clinical Medicine, Unit of Family Medicine, University of Turku and Turku University Hospital, Turku, Finland.
Welfare Division, Turku City Hospital, Turku, Finland.

Anna M Viljanen (AM)

Municipality of Lieto, Health Care Center, Lieto, Finland.
Faculty of Medicine, Department of Geriatrics, Turku City Hospital, University of Turku, Turku, Finland.

Elisa T M Heikkilä (ETM)

Faculty of Medicine, Department of Clinical Medicine, Unit of Clinical Chemistry, Turku University, Turku, Finland.
Department of Clinical Chemistry, Laboratory Division, Turku University Hospital, Hospital District of Southwest Finland, Turku, Finland.

Minna K Löppönen (MK)

Social and Health Care for Elderly, Raisio, Finland.

Raimo E Isoaho (RE)

Faculty of Medicine, Department of Clinical Medicine, Unit of Family Medicine, University of Turku and Turku University Hospital, Turku, Finland.
Social and Health Care, Vaasa, Finland.

Sirkka-Liisa Kivelä (SL)

Faculty of Medicine, Department of Clinical Medicine, Unit of Family Medicine, University of Turku and Turku University Hospital, Turku, Finland.
Faculty of Pharmacy, Division of Social Pharmacy, University of Helsinki, Helsinki, Finland.

Antti Jylhä (A)

Zora Biosciences Oy, Espoo, Finland.

Laura Viikari (L)

Faculty of Medicine, Department of Geriatrics, Turku City Hospital, University of Turku, Turku, Finland.
Welfare Division, Turku City Hospital, Turku, Finland.

Kerttu M Irjala (KM)

Faculty of Medicine, Department of Clinical Medicine, Unit of Clinical Chemistry, Turku University, Turku, Finland.

Kari J Pulkki (KJ)

HUS Diagnostic Center, Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.
Clinical Chemistry and Hematology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Reijo M H Laaksonen (RMH)

Zora Biosciences Oy, Espoo, Finland.
Finnish Cardiovascular Research Center, University of Tampere, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH